The Role of Alpha-Lactalbumin with Myoinositol in the Treatment of PCOS: A Review
Published: 2022-12-10
Page: 256-262
Issue: 2022 - Volume 5 [Issue 1]
Manish R. Pandya
Scientific Research Institute, Surendranagar and Nootan Medical College, Visnagar, Gujarat, India.
Jignesh Shah
Dr. Shah Maternity and Nursing Home, Ahmedabad, Gujarat, India.
Varsha Narayanan *
Vitamystic Healthcare, Mumbai, Maharashtra, India.
*Author to whom correspondence should be addressed.
Abstract
Polycystic Ovary Syndrome (PCOS) presents commonly in women of reproductive age group, and has a multifactorial pathogenesis involving insulin resistance and androgen excess, influenced by obesity, diet, lifestyle, metabolic factors, stress, and environmental factors. Inositols (myoinositol-MI, D-chiro inositol-DCI) are part of the therapy options to address insulin resistance in PCOS. However, many women may be inositol nonresponsive due to competitive reduction of inositol intestinal absorption, gut dysbiosis and chronic inflammation. Addition of alpha-lactalbumin can help increase intestinal absorption of inositols, as well as improve gut dysbiosis and inflammation, along with reducing insulin resistance. Presented here is a review of studies that have shown improved rates of ovulation, MI absorption and levels, as well as metabolic and hormonal parameters, when alpha-lactalbumin is added to myoinositol.
Keywords: PCOS, myoinositol, insulin resistance, alpha-lactalbumin, inositol resistance
How to Cite
Downloads
References
Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270-284.
Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. P T. 2013;38(6):336-55.
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (Sao Paulo). 2015;70(11):765-9.
Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res. 2019;150(4):333- 344.
Ali AT. Polycystic ovary syndrome and metabolic syndrome. Ceska Gynekol. 2015;80(4):279-89.
Shirazi FKH, Khodamoradi Z, Jeddi M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS). BMC Endocr Disord. 2021:21:45.
Pandya MR, Khandheria K, Golwala D. Evaluation of clinical efficacy and safety of ovaryl tablet a herbalformulation in Poly Cystic Ovarian Syndrome (PCOS). Indian Journal of Obstetrics and Gynecology Research. 2015;2(2):73-91.
Cabrera-Cruz H, Oróstica L, Plaza-Parrochia F, Torres-Pinto I, Romero C, Vega M. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. Am J Physiol Endocrinol Metab. 2020;318(2): E237-E248.
Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A comparative study of myoinositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. International Journal of Pharmaceutical Sciences and Research. 2017;8(4):1664-1670.
Agrawal A, Mahey R, Kachhawa G, Khadgawat R, Vanamail P, Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: Randomized controlled trial. Gynecol Endocrinol. 2019;35(6):511-514.
Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with Polycystic Ovarian Syndrome (PCOS): A meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198-206.
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647-658.
Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47-60.
Unfer V, Dinicola S, Laganà AS, Bizzarri M. Altered ovarian inositol ratios may account for pathological steroidogenesis in PCOS. Int J Mol Sci. 2020;21(19):7157.
Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23 (12):5512-5521.
Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575-81.
Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A combined therapy with Myo-Inositol and D-Chiro-Inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int. J Endocrinol. 2016;2016: 3204083.
Unfer V. Use of alpha-lactalbumin for the management of PCOS in inositols resistant women. European Review for Medical and Pharmacological Sciences. 2018;22:1873-1874.
Zhao X, Jiang Y, Xi H, Chen L, Feng X. Exploration of the relationship between gut microbiota and Polycystic Ovary Syndrome (PCOS): A review. Geburtshilfe und Frauenheilkunde. 2020;80(2):161–171.
Layman DK, Lönnerdal B, Fernstrom JD. Applications for α-lactalbumin in human nutrition. Nutr Rev. 2018;76(6):444-460.
Izum IH, Ishizuk AS, Inafune A, Hira T, Ozawa K, Shimizu T, Takase M, Hara H. Α-Lactalbumin hydrolysate stimulates glucagon-like peptide-2 secretion and small intestinal growth in suckling rats. J Nutr. 2009;139:1322-1327.
Au A, Gupta A, Schembri P, Cheeseman CI. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem J. 2002;367:247-254.
Petersen YM, Elnif J, Schmidt M, Sangild PT. Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets. Pediatr Res. 2002;52:498-503.
Monastra G, Sambuy Y, Ferruzza S, Ferrari D, Ranaldi G. Alpha-lactalbumin effect on Myo-inositol intestinal absorption: In vivo and In vitro. Curr Drug Deliv. 2018;15(9):1305-1311.
Cardinale V, Lepore E, Basciani S, Artale S, Nordio M, Bizzarri M, Unfer V. Positive effects of α-lactalbumin in the management of symptoms of polycystic ovary syndrome. Nutrients. 2022;14:3220.
Yamaguchi M, Yoshida K, Uchida M. Novel functions of bovine milk-derived alpha-lactalbumin: Anti-nociceptive and anti-inflammatory activity caused by inhibiting cyclooxygenase-2 and phospholipase A2. Biol. Pharm Bull. 2009;32(3):366-71.
Gao J, Guo K, Du M, Mao X. Bovine α-lactalbumin-derived peptides attenuate TNF-α-induced insulin resistance and inflammation in 3T3-L1 adipocytes through inhibiting JNK and NF-κB signaling. Food & Function. 2022; 13:2323-2335.
Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J. Ovarian Res. 2018; 11(1):38.
Hernandez Marin I, Picconi O, Laganà AS, Costabile L, Unfer V. A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients. Eur Rev Med Pharmacol Sci. 2021;25(8):3316-3324.
D’Anna R, Corrado F, Loddo S, Gullo G, Giunta LD, Benedetto A. Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: A randomized, controlled study. Sci. Rep. 2021;11:8866.